Abstract 2159P
Background
The International Society for Geriatric Oncology (SIOG) recommends the use of geriatric assessments (GA) or clinical adverse event risk predictors when managing older cancer patients. However, traditional GA and risk predictors are rarely utilized in the real-world setting due to limitations in time and resources. The objective of this study was to assess the performance of machine learning algorithms in predicting the risk of post-chemotherapy grade 3-5 toxicity in older Asian patients.
Methods
This study is based on a dataset of patients from a prospective study at the National University Cancer Institute, Singapore (NCIS) that successfully validated the CARG model in older Asian patients. In this study, 200 patients aged 70 years or older of various Asian ethnicities, with a solid tumor diagnosis and undergoing chemotherapy were prospectively recruited over the period of June 1, 2017, to January 1, 2019. We trained four machine learning models – Support Vector Machine (SVM), Random Forest (RF), Extreme Gradient Boosting (Xgboost), and Light Gradient Boosting Machine (Light DBM) to predict the outcomes of grade 3-5 (CTCAE version 4.0) adverse events post-chemotherapy.
Results
The median patient age was 74 years (IQR, 71 to 78), and 110 (55.0%) were male. 137 (68.5%) patients experienced grade 3 to 5 chemotherapy toxicity. The best-performing model for predicting grade 3-5 chemotherapy toxicity in the test set was the Xgboost model which achieved an area under the ROC curve (AUC) of 0.87. By comparison, the CARG clinical model and oncologist prediction of grade 3-5 toxicity achieved an AUC of 0.61 and 0.74 respectively in the test set. The best performing Xgboost model included elements of the CARG model in addition to clinical features such as the Karnofsky Performance Scale, number of co-morbidities and medications, current treatment line, “Timed-Up and Go”.
Conclusions
The Xgboost Machine Learning model was able to predict the occurrence of grade 3-5 toxicity post-chemotherapy in elderly Asian patients with a better performance compared to the CARG clinical model and oncologists’ predictions. These results will be further evaluated in external, prospective patient cohorts to validate them for clinical use.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National University Cancer Institute, Singapore.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2140P - Short-term quality-of-life after metastases-directed SBRT: Results of the prospective ESTRO & EORTC OligoCare cohort
Presenter: Daniela Greto
Session: Poster session 07
2141P - Symptom burden and health-related quality of life (HRQoL) in platinum-resistant or -refractory ovarian cancer (PROC): A systematic literature review (SLR)
Presenter: Nikhila Indukuri
Session: Poster session 07
2142P - Criteria for the choice of therapeutic ceiling in the hospitalized oncology patient: Healthcare impact of the multidisciplinary committee with the Intensive Care Unit (ICU)
Presenter: María Esperanza Guirao García
Session: Poster session 07
2143P - Mortality within 30 days after last dose of intravenous systemic anti-cancer therapy: Single-center, one-year, retrospective analysis
Presenter: Osman Sutcuoglu
Session: Poster session 07
2144P - The PRognostic Oncologic Plantology (PROP) website tool predicts 30-day mortality in hospitalized cancer patients on treatment
Presenter: Oriol Mirallas
Session: Poster session 07
2145P - Thromboembolic disease associated with cyclin-dependent kinase inhibitors in patients with breast cancer
Presenter: Javier López Robles
Session: Poster session 07
2146P - Cancer-associated thrombosis clinic: Experience of the Medical Oncology Department of a hospital in Spain
Presenter: Laura Ortega Morán
Session: Poster session 07
2147P - Thrombotic recurrence and bleeding complications in non-small cell lung carcinoma (NSCLC) patients with venous thromboembolism (VTE)
Presenter: Irene Gonzalez Caraballo
Session: Poster session 07
2148P - Venous thromboembolism (VTE) in patients with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitors
Presenter: Lorenzo Gervaso
Session: Poster session 07
2149P - Catheter-related thrombosis in cancer patients: Data from the registry of thrombosis and neoplasia of SEOM (TESEO)
Presenter: Francisco Pelegrín Mateo
Session: Poster session 07